Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H26N2O7 |
Molecular Weight | 418.4403 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C
InChI
InChIKey=UIAGMCDKSXEBJQ-UHFFFAOYSA-N
InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2663415Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2565839
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2663415
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2565839
Nimodipine is a dihydropyridine calcium antagonist which has been shown to dilate cerebral arterioles and increase cerebral blood flow in animals and humans. It has potential in the treatment of a range of cerebrovascular disorders. Major interest to date, however, has focused on its use in the prevention and treatment of the delayed ischaemic neurological deficits that frequently occur in patients with subarachnoid haemorrhages as a result of sustained cerebral vasospasm. Nimodipine, a Ca2+ antagonist with cerebrovasodilatory and anti-ischemic effects, binds to rat, guinea pig, and human brain membranes with high affinity (less than 1 nM). Only at higher concentrations has nimodipine been reported to block the release of some neurotransmitters and hormones from neuronal tissue.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2760631
Curator's Comment: Nimodipine has adequate brain penetration, dilates
intracranial vessels in animals and humans.
Experimental data suggest direct neuronal action of nimodipine in animals.
https://www.ncbi.nlm.nih.gov/pubmed/2565839
Originator
Sources: https://www.google.com/patents/US3799934
Curator's Comment: # Meyer et al, patented to Bayer AG
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2565839 |
0.27 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NIMOTOP Approved UseNimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). Launch Date1988 |
|||
Primary | NYMALIZE Approved UseNYMALIZE is a dihydropyridine calcium channel blocker indicated for the
improvement of neurological outcome by reducing the incidence and severity
of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH)
from ruptured intracranial berry aneurysms regardless of their post-ictus
neurological condition (i.e., Hunt and Hess Grades I-V). Launch Date2013 |
|||
Primary | NIMODIPINE Approved UseNimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8249618 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIMODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
29 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7962672 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIMODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8249618 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIMODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
47.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7962672 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIMODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8249618 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIMODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.27 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7962672 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIMODIPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5% |
NIMODIPINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
60 mg 6 times / day multiple, oral Recommended Dose: 60 mg, 6 times / day Route: oral Route: multiple Dose: 60 mg, 6 times / day Sources: |
unhealthy, 47 (21-63) n = 38 Health Status: unhealthy Condition: subarachnoid haemorrhage Age Group: 47 (21-63) Sex: M+F Population Size: 38 Sources: |
Other AEs: Death... |
120 mg 6 times / day multiple, oral Highest studied dose Dose: 120 mg, 6 times / day Route: oral Route: multiple Dose: 120 mg, 6 times / day Sources: |
unhealthy, adult n = 4 Health Status: unhealthy Condition: subarachnoid haemorrhage Age Group: adult Sex: unknown Population Size: 4 Sources: |
Other AEs: Blood pressure decreased... Other AEs: Blood pressure decreased (50%) Sources: |
2 mg/h 1 times / day multiple, intravenous Recommended Dose: 2 mg/h, 1 times / day Route: intravenous Route: multiple Dose: 2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: subarachnoid hemorrhage Age Group: adult Sex: M+F Population Size: 120 Sources: |
Other AEs: Death... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Death | grade 5, 4 patients | 60 mg 6 times / day multiple, oral Recommended Dose: 60 mg, 6 times / day Route: oral Route: multiple Dose: 60 mg, 6 times / day Sources: |
unhealthy, 47 (21-63) n = 38 Health Status: unhealthy Condition: subarachnoid haemorrhage Age Group: 47 (21-63) Sex: M+F Population Size: 38 Sources: |
Blood pressure decreased | 50% | 120 mg 6 times / day multiple, oral Highest studied dose Dose: 120 mg, 6 times / day Route: oral Route: multiple Dose: 120 mg, 6 times / day Sources: |
unhealthy, adult n = 4 Health Status: unhealthy Condition: subarachnoid haemorrhage Age Group: adult Sex: unknown Population Size: 4 Sources: |
Death | grade 5, 7 patients | 2 mg/h 1 times / day multiple, intravenous Recommended Dose: 2 mg/h, 1 times / day Route: intravenous Route: multiple Dose: 2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 120 Health Status: unhealthy Condition: subarachnoid hemorrhage Age Group: adult Sex: M+F Population Size: 120 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Magnetic resonance imaging in the evaluation of nimodipine-treated acute experimental focal cerebral ischemia. | 1986 |
|
[Ergotism with cerebral complications. Case report and review of the literature]. | 1986 Apr 5 |
|
Ca2+ modulators as antidotes to imipramine and neurotransmitter toxicity. | 1987 Sep |
|
Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. | 1988 Aug |
|
Oxytocin-induced penile erection and yawning: role of calcium and prostaglandins. | 1990 Mar |
|
Quinine-induced tinnitus in rats. | 1991 Oct |
|
Pulmonary vasoconstriction following intravenous nimodipine. | 1992 May |
|
Effects of the combination of ketoconazole and calcium channel antagonists against Candida albicans in vitro. | 1993 Jul |
|
Sinus arrest after nimodipine treatment for a head injury. | 1994 |
|
Cocaine toxicity and the calcium channel blockers nifedipine and nimodipine in rats. | 1994 Jan-Feb |
|
Dose-finding study with nimodipine: a selective central nervous system calcium channel blocker on aminophylline induced seizure models in rats. | 1998 Mar 15 |
|
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells. | 2000 Nov |
|
Calcium antagonists decrease capillary wall damage in aging hypertensive rat brain. | 2001 Mar-Apr |
|
High initial blood pressure after acute stroke is associated with poor functional outcome. | 2001 May |
|
Functional properties of Cav1.3 (alpha1D) L-type Ca2+ channel splice variants expressed by rat brain and neuroendocrine GH3 cells. | 2001 Oct 19 |
|
Calcium channel blocker, nimodipine, for the treatment of bipolar disorder during pregnancy. | 2002 Dec |
|
Possible involvement of dopaminergic neurotransmitter system in dichlorvos induced delayed neurotoxicity. | 2002 Feb |
|
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
Effects of blood pressure lowering in the acute phase of total anterior circulation infarcts and other stroke subtypes. | 2003 |
|
Cerebral vasospasm after subarachnoid hemorrhage. | 2003 Apr |
|
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. | 2003 Jan 23 |
|
Use of phenytoin and other anticonvulsant prophylaxis in patients with aneurysmal subarachnoid hemorrhage. | 2005 Dec |
|
Antioxidant effect of nimodipine in young rats after pilocarpine-induced seizures. | 2005 Sep |
|
Ion changes in spreading ischaemia induce rat middle cerebral artery constriction in the absence of NO. | 2005 Sep |
|
The L-type calcium channel blocker nimodipine mitigates cytoskeletal proteins phosphorylation in dichlorvos-induced delayed neurotoxicity in rats. | 2006 May |
|
[Effect of nimodipine on mechanisms of HL-60 cell apoptosis induced by cytarabine]. | 2007 Feb |
|
L-type calcium channel blockade on haloperidol-induced c-Fos expression in the striatum. | 2007 Nov 9 |
|
Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. | 2008 Nov |
|
Protective effect of L-type calcium channel blockers against haloperidol-induced orofacial dyskinesia: a behavioural, biochemical and neurochemical study. | 2008 Sep |
|
Chloride channels as drug targets. | 2009 Feb |
|
Cell death induced by zinc and cadmium is mediated by clusterin in cultured mouse seminiferous tubules. | 2009 Jul |
|
Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. | 2009 Sep |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Sample Use Guides
Nimodipine is given orally in the form of soft gelatin 30 mg capsules for subarachnoid hemorrhage. The recommended oral dose is 60 mg (two 30 mg capsules) every 4 hours for 21 consecutive days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22677442
Nimodipine (1-100 μM) conferred 65±13% neuroprotection in PC12 neuronal cultures upon exposure to oxygen-glucose deprivation (OGD) and 35±6% neuroprotection towards different trophic withdrawal-induced cell death measured by lactate dehydrogenase and caspase 3 activities. The time window of nimodipine conferred neuroprotection was detected during the first 5h but not at longer OGD exposures.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/15/1554
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
LIVERTOX |
NBK548041
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
NDF-RT |
N0000175421
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
NDF-RT |
N0000000069
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
WHO-ATC |
C08CA06
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
343711
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
NDF-RT |
N0000007556
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
566016
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
338611
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
||
|
WHO-VATC |
QC08CA06
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00393
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
57WA9QZ5WH
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
66085-59-4
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
m7906
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
4497
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
1463858
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1428
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
266-127-0
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
100000092273
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
Nimodipine
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
7575
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
2523
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
DTXSID5023370
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
7426
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
57WA9QZ5WH
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
4528
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
SUB09297MIG
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
758476
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
NIMODIPINE
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
1937
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
C692
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY | |||
|
D009553
Created by
admin on Fri Dec 15 18:02:29 GMT 2023 , Edited by admin on Fri Dec 15 18:02:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)